Status:
COMPLETED
Genetic Determinants of Clindamycin/Rifampin Interaction
Lead Sponsor:
Dr Valerie ZELLER
Collaborating Sponsors:
Fondation Ophtalmologique Adolphe de Rothschild
Conditions:
VA Drug Interaction
Eligibility:
All Genders
18+ years
Brief Summary
Main objective- To study the influence of the polymorphisms of nuclear receptor proteins pregnane X receptor (PXR), Liver X receptor alpha (LXRα), and Cytochrome P450 (CYP450) on the clindamycin clear...
Detailed Description
Eligible patients will be informed on the study during their hospitalisation in the unit for the treatment of bone and joint infection by the medical doctor. If they agree to participate in the study,...
Eligibility Criteria
Inclusion
- bone or joint infection
- aged ≥ 18 years old
- treatment with clindamycin/rifampin combination therapy \> 10 days
Exclusion
- prescription of another treatment with potential action on CYP450
- pregnant or breast feeding patient
Key Trial Info
Start Date :
January 1 2016
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 15 2021
Estimated Enrollment :
84 Patients enrolled
Trial Details
Trial ID
NCT03267225
Start Date
January 1 2016
End Date
April 15 2021
Last Update
October 25 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Groupe Hospitalier Diaconesses Croix Saint Simon
Paris, France, 75020